- Email: [email protected]
5071773 Hormone receptor-related bioassays
289
PATENT ABSTRACTS
95% or more and inhibits pancreatic alphaamylase by 50% or less, and then detecting pancreatic alpha-amylase with a system for the detection of alpha-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing beta-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary alpha-amylase, aluminum hydroxide and Bortadella pertussis.
5071748 MIXED BACULOVIRUS COMPOSITIONS AND USES THEREOF David W Miller assigned to Genetics Institute Inc A mixed composition polyhedral inclusion body (PIB) is provided which contains a mixture of nucleocapsids of at least two genetically distinct baculoviruses. At least one of the baculoviruses is genetically engineered to contain at least one heterologous gene. Followed ingestion of the mixed composition PIB by an insect host, a mixed viral infection ensues in the insect permitting the production therein of additional copies of the mixed composition PIB and the production of a heterologous protein encoded by the heterologous gene present in at least one of the baculoviruses.
5071763 LACTOSE HYDROLYSIS BY MUTANT STREPTOCOCCUS THERMOPHILUS George A Somkuti, Dennis H Steinberg assigned to The United States of America as represented by the Secretary of Agriculture Mutant strains of Streptococcus thermophilus having defective lactose transport systems having a phenotype gluS31, lacS-, sucS+ and bctagal+ are effective for use in processes where the hydrolysis of lactose is sought. Thermostability of these strains as well as the betagalactosidase produced allows lactose hydrolysis prior to and during pasteurization. These organisms provide the food industry with im-
proved methods of making reduced lactose dairy products.
5071764 PROCESS FOR TRANSFORMATION OF YARROWIA LIPOLYTICA Lance S Davidow, John R DeZeeuw assigned to Pfizer Inc Process for transformation of Yarrowia lipolytica, vectors useful therefor comprising DNA of a microbial vector and chromosomal DNA of Y. lipolytica and transformants comprising said vectors in E. coli and Y. lipolytica, and integrative shuttle vectors for EscherichiaYarrowia transgeneric cloning. Said vectors or subclones thereof enable creation ofY. lipolytica cloning vectors into which specific or random segments of DNA can be inserted and the resulting vectors used to transform a suitable host microbe, especialy Y. lipolytica, to improve the fermentation characteristics thereof and hence their industrial utilization. The methodology described permits the cloning of genes from a gene library of Y. lipolytica by complementation with an integrating vector.
5071773 HORMONE
RECEPTOR-RELATED BIOASSAYS
Ronald M Evans, Cary A Weinberger, Stanley Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine Thompson, Estelita S Ong assigned to The Salk Institute for Biological Studies The present invention discloses two hormone receptor-related bioassays. The first bioassay is useful for determining whether a protein suspected of being a hormone receptor has transcription-activating properties of a hormone receptor. The second bioassay is useful for evaluating whether compounds are functional ligands for receptor proteins. According to the first bioassay, cells that contain non-endogenous DNA which expresses a protein suspected of being a hormone receptor and which contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in a culture medium containing a known hormone, or an analog thereof. The cultured cells are then monitored for induction of the product of the reporter gene as an indication of functional transcription-activating
PATENT ABSTRACTS
290
binding between the hormone or hormone analog and the protein suspected of being a hormone receptor. According to the second bioassay, cells that contain non-endogenous DNA which expresses hormone receptor or a functional engineered or modified form thereof, and which also contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in culture medium containing at least one compound whose ability to functionally bind the receptor protein is sought to be determined. The cultured cells are then monitored for induction of the product of the report gene as an indicator of functional binding between the compound and the receptor.
5071962 NUCLEOTIDE, DEDUCED AMINO ACID SEQUENCE, ISOLATION AND PURIFICATION OF HEATSHOCK CHLAMYDIAL PROTEINS Richard P Morrison, Harlan D Caldwell assigned to The United State of America as represented by the Department of Health and Human Services The present invention relates to novel polypeptides comprising a unique chlamydialspecific primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokatyotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.
signed to Yeda Research and Developement Ltd
Co
Human DNA encoding enzymes having (2’-5’) oligo A synthetase has been sequenced. The amino acid sequences of the enzymes have been deduced. Antigenic peptides have been prepared and have been used to raise antibodies which recognize and immunoprecipitate the 40 kd, 46 kd, 67 kd and 100 kd forms of (2-S) oligo A syntheta% Methods of monitoring interferon activity in a subject are presented.
5071972 DNA SEOUENCES ENCODING NOVEE THROMBOLYTIC PROTEINS Glenn R Larsen assigned to Genetics Institute Inc Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.
5071983 THERAPEUTIC
NUCLEOSIDES
George W Koszalka, Thomas Krenitsky signed to Burroughs Wellcome Co
as-
This invention relates to certain derivatives of 2, 3’-dideoxycytidine and their use in medical therapy particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations and processes for the manufacture of the compounds according to the invention.
5071654 ION CHANNEL PROPERTIES DELTA ENDOTOXINS
OF
Leigh H English assigned to Ecogen Inc
5071963 INTERFERON-INDUCED HUMAN (2’-5’) OLIGO A St%%HETASE Michel Revel, Judit Chebath, Rehovot, Israel as-
The present invention relates to an in vitro method for measuring the toxicity of a deltaendotoxin of Bacillus thuringiensis by evaluating the ability of said endotoxin to form an ion channel in a phospholipid vesicle.
PATENT ABSTRACTS
95% or more and inhibits pancreatic alphaamylase by 50% or less, and then detecting pancreatic alpha-amylase with a system for the detection of alpha-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing beta-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary alpha-amylase, aluminum hydroxide and Bortadella pertussis.
5071748 MIXED BACULOVIRUS COMPOSITIONS AND USES THEREOF David W Miller assigned to Genetics Institute Inc A mixed composition polyhedral inclusion body (PIB) is provided which contains a mixture of nucleocapsids of at least two genetically distinct baculoviruses. At least one of the baculoviruses is genetically engineered to contain at least one heterologous gene. Followed ingestion of the mixed composition PIB by an insect host, a mixed viral infection ensues in the insect permitting the production therein of additional copies of the mixed composition PIB and the production of a heterologous protein encoded by the heterologous gene present in at least one of the baculoviruses.
5071763 LACTOSE HYDROLYSIS BY MUTANT STREPTOCOCCUS THERMOPHILUS George A Somkuti, Dennis H Steinberg assigned to The United States of America as represented by the Secretary of Agriculture Mutant strains of Streptococcus thermophilus having defective lactose transport systems having a phenotype gluS31, lacS-, sucS+ and bctagal+ are effective for use in processes where the hydrolysis of lactose is sought. Thermostability of these strains as well as the betagalactosidase produced allows lactose hydrolysis prior to and during pasteurization. These organisms provide the food industry with im-
proved methods of making reduced lactose dairy products.
5071764 PROCESS FOR TRANSFORMATION OF YARROWIA LIPOLYTICA Lance S Davidow, John R DeZeeuw assigned to Pfizer Inc Process for transformation of Yarrowia lipolytica, vectors useful therefor comprising DNA of a microbial vector and chromosomal DNA of Y. lipolytica and transformants comprising said vectors in E. coli and Y. lipolytica, and integrative shuttle vectors for EscherichiaYarrowia transgeneric cloning. Said vectors or subclones thereof enable creation ofY. lipolytica cloning vectors into which specific or random segments of DNA can be inserted and the resulting vectors used to transform a suitable host microbe, especialy Y. lipolytica, to improve the fermentation characteristics thereof and hence their industrial utilization. The methodology described permits the cloning of genes from a gene library of Y. lipolytica by complementation with an integrating vector.
5071773 HORMONE
RECEPTOR-RELATED BIOASSAYS
Ronald M Evans, Cary A Weinberger, Stanley Hollenberg, Vincent Giguere, Jeffrey Arriza, Catherine Thompson, Estelita S Ong assigned to The Salk Institute for Biological Studies The present invention discloses two hormone receptor-related bioassays. The first bioassay is useful for determining whether a protein suspected of being a hormone receptor has transcription-activating properties of a hormone receptor. The second bioassay is useful for evaluating whether compounds are functional ligands for receptor proteins. According to the first bioassay, cells that contain non-endogenous DNA which expresses a protein suspected of being a hormone receptor and which contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in a culture medium containing a known hormone, or an analog thereof. The cultured cells are then monitored for induction of the product of the reporter gene as an indication of functional transcription-activating
PATENT ABSTRACTS
290
binding between the hormone or hormone analog and the protein suspected of being a hormone receptor. According to the second bioassay, cells that contain non-endogenous DNA which expresses hormone receptor or a functional engineered or modified form thereof, and which also contain a DNA sequence encoding an operative hormone responsive promoter/enhancer element linked to an operative reporter gene, are cultured, the culturing being conducted in culture medium containing at least one compound whose ability to functionally bind the receptor protein is sought to be determined. The cultured cells are then monitored for induction of the product of the report gene as an indicator of functional binding between the compound and the receptor.
5071962 NUCLEOTIDE, DEDUCED AMINO ACID SEQUENCE, ISOLATION AND PURIFICATION OF HEATSHOCK CHLAMYDIAL PROTEINS Richard P Morrison, Harlan D Caldwell assigned to The United State of America as represented by the Department of Health and Human Services The present invention relates to novel polypeptides comprising a unique chlamydialspecific primary structural conformation and one or more of the biological properties of eukaryotic or prokaryotic stress-response proteins which are characterized by being the expressed products of an endogenous or exogenous DNA sequence in a eukaryotic or prokatyotic host cell. Sequences coding for part or all of the amino acid residues of the chlamydial HypA or HypB protein or for analogs thereof may be incorporated into autonomously replicating vectors employed to transform or transfect suitable procaryotic or eukaryotic host cells such as bacteria or vertebrate cells in culture. The HypB protein is a member of the family of stress response proteins referred to as HSP60. Products of expression of the DNA sequences display the identical physical, immunological, and histological properties as the chlamydial proteins isolated from natural, non-recombinant, organisms.
signed to Yeda Research and Developement Ltd
Co
Human DNA encoding enzymes having (2’-5’) oligo A synthetase has been sequenced. The amino acid sequences of the enzymes have been deduced. Antigenic peptides have been prepared and have been used to raise antibodies which recognize and immunoprecipitate the 40 kd, 46 kd, 67 kd and 100 kd forms of (2-S) oligo A syntheta% Methods of monitoring interferon activity in a subject are presented.
5071972 DNA SEOUENCES ENCODING NOVEE THROMBOLYTIC PROTEINS Glenn R Larsen assigned to Genetics Institute Inc Thrombolytic proteins are disclosed which have tissue plasminogen-type activity. The proteins are characterized by modification within the 94 amino acid N-terminus, and/or at Arg-275, and/or at one or more of the N-linked glycosylation sites. Methods for making these proteins are disclosed as are therapeutic compositions containing same.
5071983 THERAPEUTIC
NUCLEOSIDES
George W Koszalka, Thomas Krenitsky signed to Burroughs Wellcome Co
as-
This invention relates to certain derivatives of 2, 3’-dideoxycytidine and their use in medical therapy particularly in the treatment of HIV infections. Also provided are pharmaceutical formulations and processes for the manufacture of the compounds according to the invention.
5071654 ION CHANNEL PROPERTIES DELTA ENDOTOXINS
OF
Leigh H English assigned to Ecogen Inc
5071963 INTERFERON-INDUCED HUMAN (2’-5’) OLIGO A St%%HETASE Michel Revel, Judit Chebath, Rehovot, Israel as-
The present invention relates to an in vitro method for measuring the toxicity of a deltaendotoxin of Bacillus thuringiensis by evaluating the ability of said endotoxin to form an ion channel in a phospholipid vesicle.